Combination of Hypoxia and RNA-Interference Targeting VEGF Induces Apoptosis in Hepatoma Cells Via Autocrine Mechanisms

Current Pharmaceutical Biotechnology

Volumn 13, Issue 11, 2012, Pages 2290-2298

  Raskopf, Esther ^a   Vogt, Annabelle ^a   Decker, Georges ^a   Hirt, Sarah ^a   Daskalow, Katjana ^b   Cramer, Thorsten ^b   Standop, Jens ^a   Gonzalez Carmona, Maria Angeles ^a   Sauerbruch, Tilman ^a   Schmitz, Volker ^a  

^a UNIVERSITY OF BONN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Autocrine mechanisms; Hepatocellular carcinoma; Hypoxia; RNA interference

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; NEUROPILIN 1; NEUROPILIN 2; PROTEIN KINASE B; SMALL INTERFERING RNA; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEEDBACK, PHYSIOLOGICAL; MAP KINASE KINASE 4; MICE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84873432966     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112802502088     Document Type: Article

References (41)

1. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev., 2003, 3(10), 721-732.
2. Forsythe, J.A.; Jiang, B.H.; Iyer, N.V.; Agani, F.; Leung, S.W.; Koos, R.D.; Semenza, G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol., 1996, 16(9), 4604-4613.
3. Yu, P.; Kodadek, T. Dynamics of the hypoxia-inducible factor-1-vascular endothelial growth factor promoter complex. J. Biol. Chem., 2007, 282(48), 35035-35045.
4. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86(3), 353-364.
5. Bergers, G.; Benjamin, L.E. Tumorigenesis and the angiogenic switch. Nat. Rev., 2003, 3(6), 401-410.
6. Sugimachi, K.; Tanaka, S.; Terashi, T.; Taguchi, K.; Rikimaru, T. The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression. Surgery, 2002, 131(Suppl 1), S135-141.
7. Schoeffner, D.J.; Matheny, S.L.; Akahane, T.; Factor, V.; Berry, A.; Merlino, G.; Thorgeirsson, U.P. VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Lab. Investig. J. Technical Methods Pathol., 2005, 85(5), 608-623.
8. Das, B.; Yeger, H.; Tsuchida, R.; Torkin, R.; Gee, M.F.; Thorner, P.S.; Shibuya, M.; Malkin, D.; Baruchel, S. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res., 2005, 65(16), 7267-7275.
9. Weigand, M.; Hantel, P.; Kreienberg, R.; Waltenberger, J. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis, 2005, 8(3), 197-204.
10. Lacal, P.M.; Ruffini, F.; Pagani, E.; D'Atri, S. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int. J. Oncol., 2005, 27(6), 1625-1632.
11. Shibuya, M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct. Funct., 2001, 26(1), 25-35.
12. Hicklin, D.J.; Ellis, L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol., 2005, 23(5), 1011-1027.
13. Shibuya, M.; Claesson-Welsh, L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res., 2006, 312(5), 549-560.
14. Ng, I.O.; Poon, R.T.; Lee, J.M.; Fan, S.T.; Ng, M.; Tso, W.K. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am. J. Clin. Pathol., 2001, 116(6), 838-845.
15. Yamaguchi, R.; Yano, H.; Iemura, A.; Ogasawara, S.; Haramaki, M.; Kojiro, M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology, (Baltimore, Md., 1998, 28(1), 68-77.
16. Yao, D.F.; Wu, X.H.; Zhu, Y.; Shi, G.S.; Dong, Z.Z.; Yao, D.B.; Wu, W.; Qiu, L.W.; Meng, X.Y. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis. Int., 2005, 4(2), 220-226.
17. Lau, W.Y. Primary liver tumors. Semin. Surg. Oncol., 2000, 19(2), 135-144.
18. Okuda, K. Hepatocellular carcinoma. J. Hepatol., 2000, 32(1), 225-237.
19. Schmitz, V.; Vilanueva, H.; Raskopf, E.; Hilbert, T.; Barajas, M.; Dzienisowicz, C.; Gorschluter, M.; Strehl, J.; Rabe, C.; Sauerbruch, T.; Prieto, J.; Caselmann, W.H.; Qian, C. Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice. Gene Ther., 2006, 13(16), 1198-1205.
20. Raskopf, E.; Vogt, A.; Sauerbruch, T.; Schmitz, V. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J. Hepatol., 2008, 49(6), 977-984.
21. Filleur, S.; Courtin, A.; Ait-Si-Ali, S.; Guglielmi, J.; Merle, C.; Harel-Bellan, A.; Clezardin, P.; Cabon, F. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res., 2003, 63(14), 3919-3922.
22. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983, 65(1-2), 55-63.
23. Kornek, M.; Lukacs-Kornek, V.; Limmer, A.; Raskopf, E.; Becker, U.; Klockner, M.; Sauerbruch, T.; Schmitz, V. DOTAP formulated (immune-stimulatory) VEGF-A siRNA increased antitumoral efficacy in orthotopic HCC in murine liver fibrosis. Mol. Med., (Cambridge, Mass, 2008, 14(7-8),365-373.
24. Kornek, M.; Raskopf, E.; Tolba, R.; Becker, U.; Klockner, M.; Sauerbruch, T.; Schmitz, V. Accelerated orthotopic hepatocellular carcinomas growth is linked to increased expression of proangiogenic and prometastatic factors in murine liver fibrosis. Liver Int., 2008, 28(4), 509-518.
25. Schmitz, V.; Raskopf, E.; Gonzalez-Carmona, M.A.; Vogt, A.; Rabe, C.; Leifeld, L.; Kornek, M.; Sauerbruch, T.; Caselmann, W.H. Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model. Gut, 2007, 56(2), 271-278.
26. Ocker, M.; Alajati, A.; Ganslmayer, M.; Zopf, S.; Luders, M.; Neureiter, D.; Hahn, E.G.; Schuppan, D.; Herold, C. The histonedeacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J. Cancer Res. Clin. Oncol., 2005, 131(6), 385-394.
27. Jin, S.; DiPaola, R.S.; Mathew, R.; White, E. Metabolic catastrophe as a means to cancer cell death. J. Cell Sci., 2007, 120(Pt 3), 379-383.
28. Llovet, J.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Raoul, J.; Zeuzem, S. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). J. Clin. Oncol., 2007, 25(Suppl.), 18.
29. Nilsson, M.B.; Zage, P.E.; Zeng, L.; Xu, L.; Cascone, T.; Wu, H.K.; Saigal, B.; Zweidler-McKay, P.A.; Heymach, J.V. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene, 2010, 29(20),2938-2949.
30. Salceda, S.; Caro, J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem., 1997, 272(36), 22642-22647.
31. von Marschall, Z.; Cramer, T.; Hocker, M.; Finkenzeller, G.; Wiedenmann, B.; Rosewicz, S. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut, 2001, 48(1), 87-96.
32. Huang, G.W.; Yang, L.Y.; Lu, W.Q. Expression of hypoxiainducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival. World J. Gastroenterol., 2005, 11(11), 1705-1708.
33. Detwiller, K.Y.; Fernando, N.T.; Segal, N.H.; Ryeom, S.W.; D'Amore, P.A.; Yoon, S.S. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res., 2005, 65(13), 5881-5889.
34. Talapatra, S.; Thompson, C.B. Growth factor signaling in cell survival: implications for cancer treatment. J. Pharmacol. Exp. Ther., 2001, 298(3), 873-878.
35. Dhanasekaran, D.N.; Reddy, E.P. JNK signaling in apoptosis. Oncogene, 2008, 27(48), 6245-6251.
36. Kunz, M.; Ibrahim, S.; Koczan, D.; Thiesen, H.J.; Kohler, H.J.; Acker, T.; Plate, K.H.; Ludwig, S.; Rapp, U.R.; Brocker, E.B.; van Muijen, G.N.; Flory, E.; Gross, G. Activation of c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) is critical for hypoxia-induced apoptosis of human malignant melanoma. Cell Growth Differ., 2001, 12(3), 137-145.
37. Staton, C.A.; Kumar, I.; Reed, M.W.; Brown, N.J. Neuropilins in physiological and pathological angiogenesis. J. Pathol., 2007, 212(3), 237-248.
38. Bachelder, R.E.; Lipscomb, E.A.; Lin, X.; Wendt, M.A.; Chadborn, N.H.; Eickholt, B.J.; Mercurio, A.M. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res., 2003, 63(17), 5230-5233.
39. Castro-Rivera, E.; Ran, S.; Thorpe, P.; Minna, J.D. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc. Natl. Acad. Sci. USA, 2004, 101(31), 11432-11437.
40. Lee, T.H.; Seng, S.; Sekine, M.; Hinton, C.; Fu, Y.; Avraham, H.K.; Avraham, S. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med., 2007, 4(6), e186.
41. Lee, B.L.; Kim, W.H.; Jung, J.; Cho, S.J.; Park, J.W.; Kim, J.; Chung, H.Y.; Chang, M.S.; Nam, S.Y. A hypoxia-independent upregulation of hypoxia-inducible factor-1 by AKT contributes to angiogenesis in human gastric cancer. Carcinogenesis, 2008, 29(1), 44-51.